United Therapeutics (UTHR) Expected to Announce Quarterly Earnings on Wednesday

United Therapeutics (NASDAQ:UTHR) is anticipated to issue its quarterly earnings data before the market opens on Wednesday, February 19th. Analysts expect the company to announce earnings of $6.54 per share and revenue of $734.74 million for the quarter.

United Therapeutics Stock Up 0.0 %

UTHR stock opened at $370.58 on Tuesday. The business’s fifty day simple moving average is $362.00 and its two-hundred day simple moving average is $359.42. United Therapeutics has a twelve month low of $211.61 and a twelve month high of $417.82. The firm has a market cap of $16.55 billion, a price-to-earnings ratio of 16.27, a PEG ratio of 0.92 and a beta of 0.57.

Analyst Ratings Changes

UTHR has been the topic of a number of recent analyst reports. Argus increased their target price on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. The Goldman Sachs Group increased their price target on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. HC Wainwright increased their price target on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. UBS Group increased their price target on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, Oppenheimer increased their price target on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $382.08.

Insiders Place Their Bets

In other news, Director Louis W. Sullivan sold 26,209 shares of the firm’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total value of $9,781,722.98. Following the completion of the transaction, the director now directly owns 5,051 shares in the company, valued at $1,885,134.22. This trade represents a 83.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $372.75, for a total value of $3,727,500.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at $960,576.75. The trade was a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 121,864 shares of company stock valued at $44,516,965. 11.90% of the stock is currently owned by corporate insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.